Soligenix, Inc. (NASDAQ:SNGX) Short Interest Update

Soligenix, Inc. (NASDAQ:SNGX) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 14,600 shares, a decrease of 67.1% from the December 15th total of 44,400 shares. Currently, 0.6% of the shares of the stock are sold short. Based on an average daily volume of 53,700 shares, the short-interest ratio is presently 0.3 days.

Soligenix Stock Down 16.9 %

Shares of NASDAQ SNGX traded down $0.53 during midday trading on Tuesday, reaching $2.60. 10,427,668 shares of the company were exchanged, compared to its average volume of 1,347,623. The stock’s 50-day moving average price is $3.26 and its 200-day moving average price is $3.78. The stock has a market cap of $6.53 million, a P/E ratio of -0.35 and a beta of 1.77. Soligenix has a one year low of $1.83 and a one year high of $14.92.

Institutional Trading of Soligenix

An institutional investor recently bought a new position in Soligenix stock. Stephens Inc. AR bought a new position in shares of Soligenix, Inc. (NASDAQ:SNGX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 46,262 shares of the biopharmaceutical company’s stock, valued at approximately $184,000. Stephens Inc. AR owned 4.69% of Soligenix at the end of the most recent reporting period. 3.60% of the stock is currently owned by institutional investors.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.